Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07090564 · ClinicalTrials.gov registry record
Treatment Outcomes in PASC Patients With Neurocognitive Impairment
A clinical trial, sponsored by Ohio State University.
- Completed
- Registry status
- 171
- Enrollment target
NCT07090564: Completed study, sponsored by Ohio State University.
NCT07090564 is a clinical trial that has completed, run by Ohio State University. The registered enrollment target is 171 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07090564 has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 171 participants
- Enrollment target
Study Summary
Longitudinal study collecting retrospective and prospective data on treatments received and change in quality of life among patients with neurocognitive symptoms attending a Long COVID clinic
Primary Outcome
The PROMIS29 is a well-validated measure of quality of life in multiple domains. Study subjects will complete PROMIS29 questionnaire at the first clinic visit, and again 6 months later. The outcome will consist of change in T-scores on the PROMIS29 from t=0 to t=6 months.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2024-04-01 |
What the finished NCT07090564 record still lists
NCT07090564 is an observational study that tracks outcomes without assigning an intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07090564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07090564 about?
NCT07090564 is a clinical study titled "Treatment Outcomes in PASC Patients With Neurocognitive Impairment". Longitudinal study collecting retrospective and prospective data on treatments received and change in quality of life among patients with neurocognitive symptoms attending a Long COVID clinic
What is the current status of trial NCT07090564?
This trial is currently completed. The enrollment target is 171 participants. The study started on 2022-10-12. Estimated completion is 2024-04-01.
Who is sponsoring clinical trial NCT07090564?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI